Literature DB >> 10473114

Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines.

M R Posner1, L A Cavacini, M P Upton, K C Tillman, E R Gornstein, C M Norris.   

Abstract

Because regional spread to lymph nodes without systemic spread is a relatively common event in squamous cell cancer of the head and neck (SCCHN), it is possible that lymphoid-related receptors or cytokines might directly impact the growth of these tumors. In the present study, we have shown by flow cytometry and Western blotting that the central lymphoid regulatory molecule, CD40, is expressed on the surface of all seven SCCHN tumor cell lines studied. Tumor cell lines also expressed epidermal growth factor (EGF) receptor, MHC class I, and CD95 (Fas) but did not uniformly express other important lymphoid regulatory molecules such as CD80, CD86, or interleukin (IL) 2 receptor components. CD40 ligation by trimeric CD40 ligand (CD40L) resulted in a 20-45% inhibition of tumor cell growth in three of seven cell lines tested. The cytokines IL-1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-10, IL-11, and IL-15 neither inhibited nor stimulated growth in any of the cell lines tested. EGF had pleiotropic effects on cell growth; it inhibited growth in two cell lines, stimulated growth in one cell line, and had no effect in four cell lines. When coligation by EGF and CD40L was studied, additive or supra-additive growth inhibition was seen in four cell lines. Three cell lines were unaffected by EGF, CD40, or coligation with both reagents. Examination of tumor tissues from 12 previously untreated patients representing a broad spectrum of patients presenting with SCCHN demonstrated CD40 expression in all 12 tumor specimens. This study supports the notion that CD40 is a regulatory molecule for the growth of SCCHN. The important role of CD40-CD40L interactions in the regulation of immune cells in the lymph node and the unique high-level expression of CD40L by these immune cells lend support to the hypothesis that this ligand/receptor pair is an important mediator of cell growth in SCCHN.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473114

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

Review 2.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Authors:  Gregory L Beatty; Yan Li; Kristen B Long
Journal:  Expert Rev Anticancer Ther       Date:  2016-12-14       Impact factor: 4.512

Review 3.  Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Authors:  Jessica M Moskovitz; Jennifer Moy; Tanguy Y Seiwert; Robert L Ferris
Journal:  Oncologist       Date:  2017-05-15

Review 4.  Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

Authors:  Jennifer D Moy; Jessica M Moskovitz; Robert L Ferris
Journal:  Eur J Cancer       Date:  2017-03-18       Impact factor: 9.162

5.  TNFα regulates the localization of CD40 in lipid rafts of glioma cells.

Authors:  Richa Tewari; Saurav Roy Choudhury; Veer Singh Mehta; Ellora Sen
Journal:  Mol Biol Rep       Date:  2012-06-15       Impact factor: 2.316

Review 6.  Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.

Authors:  Julie E Bauman; Robert L Ferris
Journal:  Cancer       Date:  2013-11-12       Impact factor: 6.860

7.  Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

Authors:  Laetitia Cicchelero; Sofie Denies; Bert Devriendt; Hilde de Rooster; Niek N Sanders
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

8.  Analysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer.

Authors:  Jiang Du; Lin Zhang
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

Review 9.  Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.

Authors:  Geon-Tae Park; Kyung-Chul Choi
Journal:  Oncotarget       Date:  2016-09-06

Review 10.  The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma.

Authors:  Peng Liao; Haofan Wang; Ya-Ling Tang; Ya-Jie Tang; Xin-Hua Liang
Journal:  Front Immunol       Date:  2019-10-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.